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This randomized, open-label, active-controlled, dose-
ﬁnding phase IIb study evaluated the efﬁcacy and safety
of trabedersen (AP 12009) administered intratumorally
by convection-enhanced delivery compared with stan-
dard chemotherapy in patients with recurrent/refractory
high-grade glioma. One hundred and forty-ﬁve patients
with central reference histopathology of recurrent/
refractory glioblastoma multiforme (GBM) or anaplastic
astrocytoma (AA) were randomly assigned to receive tra-
bedersen at doses of 10 or 80 mM or standard che-
motherapy (temozolomide or procarbazine/lomustine/
vincristine). Primary endpoint was 6-month tumor con-
trol rate, and secondary endpoints included response at
further timepoints, survival, and safety. Six-month
tumor control rates were not signiﬁcantly different in
the entire study population (AA and GBM). Prespeciﬁed
AA subgroup analysis showed a signiﬁcant beneﬁt
regarding the 14-month tumor control rate for 10 mM
trabedersenvschemotherapy(p 5 .0032).The2-yearsur-
vival rate had a trend for superiority for 10 mMt r a b e d e r -
sen vs chemotherapy (p 5 .10). Median survival for
10 mM trabedersen was 39.1 months compared with
35.2 months for 80 mM trabedersen and 21.7 months
for chemotherapy (not signiﬁcant). In GBM patients,
response and survival results were comparable among
the 3 arms. Exploratory analysis on GBM patients aged
≤55 years with Karnofsky performance status >80% at
baseline indicated a 3-fold survival at 2 and 3 years for
10 mM trabedersen vs chemotherapy. The frequency of
patients with related or possibly drug-related adverse
events was higher with standard chemotherapy (64%)
thanwith80 mMtrabedersen(43%)and10 mMtrabeder-
sen (27%). Superior efﬁcacy and safety for 10 mMt r a b e -
dersen over 80 mM trabedersen and chemotherapy and
positive risk–beneﬁt assessment suggest it as the optimal
doseforfurtherclinicaldevelopmentinhigh-gradeglioma.
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he high-grade gliomas, mainly anaplastic astrocy-
toma (AA; WHO grade III) and glioblastoma
multiforme (GBM; WHO grade IV), represent
about 60% of all primary malignant brain tumors.
Prognosis in these cases has only marginally improved
despite technical advances in neurosurgery and radio-
therapy and the approval of novel anticancer agents.
Chemotherapy with the alkylating agent temozolomide
(TMZ) has shown a clinically meaningful and statisti-
cally signiﬁcant survival beneﬁt in patients with newly
diagnosed GBM with a median survival of 14.6
months with a combination of radiotherapy and TMZ
vs 12.1 months with radiotherapy alone.
1 The respective
5-year survival rates were 9.8% vs 1.9%.
2 However,
overall survival (OS) is still poor, especially in patients
with recurrent or refractory tumors with a median survi-
val of 11.3 months for patients with AA and 7.4 months
for patients with GBM.
3
The transforming growth factor 2 (TGF-b2) is over-
expressed in more than 90% of high-grade gliomas,
and its levels are closely related to tumor progres-
sion.
4,5,6 Inhibition of TGF-b2 in tumor tissue leads to
reversal of tumor-induced immune suppression as
well as inhibition of tumor growth, invasion, and
metastasis.
7,8,9
Trabedersen (AP 12009) is a synthetic antisense phos-
phorothioate oligodeoxynucleotide complementary to
the mRNA of the human TGF-b2 gene, developed as a
novel, targeted treatment for patients with high-grade
glioma.
10
The safety and efﬁcacy of trabedersen has been estab-
lished through various pharmacokinetic and toxicology
studies, both in vitro and in vivo.
11 In 3 phase I/II
dose escalation studies, adult patients with recurrent or
refractory AA or GBM and evidence of tumor pro-
gression were treated with trabedersen.
12 The
maximum tolerated dose was not reached despite up to
a 64-fold increase in the administered concentration.
Long-lasting complete remissions were observed at
doses of 10 and 80 mM trabedersen.
The current randomized and controlled phase IIb
study evaluated the efﬁcacy and safety of 2 doses (10
and 80 mM) of trabedersen in comparison with standard
chemotherapy in patients with recurrent high-grade
glioma of either AA or GBM.
Methods
This study was conducted in accordance with the
International Conference on Harmonisation (ICH)
Consolidated Good Clinical Practice (GCP) Guideline
E6 (Note for Guidance CPMP/135/95), the ethical prin-
ciples of the Declaration of Helsinki, and the rules of the
EU Directive 2001/20/EC. The study protocol was fully
approved by regulatory authorities and Independent
Ethics Committees/Institutional Review Boards.
Written informed consent was obtained from all
patients. An independent Data and Safety Monitoring
Board periodically reviewed safety and efﬁcacy data.
Study design
The study was multinational, open-label, randomized,
and active controlled. Patients were randomized in a
1:1:1 ratio using a centralized randomization procedure
to treatment with either 10 mM trabedersen, 80 mM tra-
bedersen, or standard chemotherapy.
Main inclusion criteria were: male or female patients
between 18 and 75 years of age with a reference
neuropathology-conﬁrmed diagnosis of recurrent/
refractory AA or GBM, Karnofsky performance status
(KPS) ≥70% at baseline, with tumor lesions ≤50 cm
3,
and a measurable enhancing tumor lesion in MRI with
a diameter ≤4.5 cm. Main exclusion criteria were:
patients with tumor surgery within the last 2 weeks,
radiotherapy within 8 weeks, chemotherapy within 4
weeks, or a baseline MRI showing a signiﬁcant mass
effect.
The diagnosis of AA or GBM was conﬁrmed by
central neuropathology assessment of tissue specimens
(Institute for Neuropathology, German Brain Tumor
Reference Center, University Hospital Bonn, Germany).
Treatment
The planned duration of treatment in the study was
approximately 6 months in all 3 treatment arms. The
survival status of all patients was followed for at least
48 months.
The standard chemotherapy control was either TMZ
(150–200 mg/m
2 on days 1–5 in 28-day cycles) or pro-
carbazine/CCNU (N-(2-chloroethyl)-N′-cyclohexyl-N-
nitrosourea; lomustine)/vincristine (PCV; lomustine
110 mg/m
2 on day 1, procarbazine 60 mg/m
2 on days
8–21, and vincristine 1.4 mg/m
2 on days 8 and 29 in
56-day cycles) depending on patient’s previous therapy:
TMZ if the patient had not been treated with TMZ
before (35 patients) and PCV if prior TMZ treatment
had failed (10 patients). Study treatment for patients of
the standard chemotherapy group included up to 6 treat-
ment cycles with TMZ or 3 treatment cycles with PCV.
Patients showing a response to therapy might have con-
tinued treatment at the discretion of the investigator.
Patients in the trabedersen groups received up to 11
treatment cycles (14 days per cycle). One cycle consisted
of trabedersen for 7 days with a ﬂow rate of 4 mL/min,
followed by isotonic saline for 7 days with a ﬂow rate of
1 mL/min. The trabedersen dose per cycle was
2.48 mg (10 mM group) or 19.81 mg (80 mM group).
Trabedersen was infused intratumorally using
convection-enhanced delivery (CED) via a subcutaneous
port access system connected to an external pump allow-
ing outpatient treatment. The CED technique allows a
highly efﬁcient, homogeneous, and targeted adminis-
tration of the drug, bypassing the blood–brain
barrier.
13,14 In contrast to other CED studies,
15,16 a
single catheter was placed into the solid and contrast-
enhancing area of the largest tumor lesion. The drug
delivery system was implanted 2 days before the start
of the infusion.
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This randomized and controlled phase II study was
designed to be hypothesis generating. The primary end-
point was the comparison of the 2 trabedersen dose
groups for the tumor control rate after 6 months using
Fisher’s exact test at a 2-sided signiﬁcance level of 5%.
In addition, as the internal control, the trabedersen
groups were compared descriptively with the standard
chemotherapy group. Tumor assessments were done
via central, blinded MRI readings of 2 independent radi-
ologists and 1 adjudicator using the classical Macdonald
criteria.
17 The tumor control rate was deﬁned as the per-
centage of patients with complete response (CR) +
partial response (PR) + stable disease (SD).
Assuming a tumor control rate of 50% in the 80 mM
trabedersen group and of 20% in the 10 mM trabedersen
group, 32 evaluable patients per arm were needed to give
80% power to reject the null hypothesis of no difference
between the 2 trabedersen groups at an a-level of 10%.
Assuming a dropout rate of 18%, 39 GBM patients per
arm were planned to be randomized. About 8 AA
patients were expected to be included in each treatment
arm, resulting in a total of 141 patients to be randomized.
Secondary endpoints included response at time points
other than 6 months, with 14 months as the last time
point with sufﬁcient MRI data available for interpret-
able analysis. Further secondary endpoints included sur-
vival, progression-free survival, and safety. The OS was
calculated from the date of randomization to date of
death and analyzed using the Kaplan–Meier method-
ology. Patients who had not died at the time of analysis
or had been lost to follow-up were censored at the time
of their last survival assessment.
Exploratory analyses were planned to be done separ-
ately for the prespeciﬁed subpopulations of AA and
GBM patients. An additional exploratory analysis was
done on GBM patients with the prognostic factors age
≤55 years and KPS .80%.
Adverse events (AEs) were graded according to the
National Cancer Institute–Common Toxicity Criteria
(NCI-CTC), version 2.0.
Results
Altogether 145 patients were randomized, 103 with
recurrent GBM and 42 with recurrent AA. Eight trabe-
dersen patients discontinued before catheter-port
implantation and 2 standard chemotherapy patients dis-
continued before start of treatment, thus the safety
population included 135 patients. One trabedersen
patient discontinued after catheter-port surgery but
before start of treatment. Therefore, a total of 134
patients were treated with study medication (40 with
10 mM trabedersen, 49 with 80 mM trabedersen, and
45 with standard chemotherapy: 35 with TMZ and 10
with PCV) and represented the primary efﬁcacy popu-
lation. During the treatment period, 83 patients discon-
tinued the study due to disease progression (57), AEs (8),
patient request (6), death(5), study drug toxicity (2), loss
to follow-up (1), and other reasons (4).
All patients had previous ﬁrst-line tumor surgery, and
91% had previous ﬁrst-line radiotherapy (Table 1). The
10 mM trabedersen group included more patients .55
years (43%) than the 80 mM trabedersen (18%) or the
standard chemotherapy (29%) group. Patients of the
10 mM trabedersen group also had the largest total
tumor volume at baseline (Table 1). Almost all patients
had brain edema at baseline.
Patients received a median of 7 and 6 treatment cycles
in the 10 and 80 mM trabedersen groups, respectively.
TMZ-treated patients (n ¼ 35) received a median of 6
treatment cycles and PCV-treated patients (n ¼ 10) a
median of 1 treatment cycle. The median overall treat-
ment duration was 91 days in the 10 mM and 78 days
in the 80 mM trabedersen groups, and 145 days for
TMZ vs 29 days for PCV. The short treatment duration
in PCV-treated patients could be explained by their
higher median age at baseline (54 years) compared
with TMZ-treated patients (43 years) and the associated
inferior bone marrow capacity and prognosis.
Efﬁcacy in the entire study population
Tumor control rate at 6 months (Table 2) in the entire
study population was nonsigniﬁcantly higher in the
10 mM trabedersen group (33%) compared with
the 80 mM trabedersen group (20%, p ¼ .1298) and
the standard chemotherapy group (27%, p ¼ .6219).
After 14 months, the 10 mM trabedersen group had the
highest tumor control rate (23%) compared with the
80 mM trabedersen group (8%, p ¼ .1197) and the stan-
dard chemotherapy group (7%, p ¼ .0529) (Table 2).
Median survival was 12.0 months (95% CI: 7.0–26.6)
with the 10 mM trabedersen group compared with 13.1
months with the 80 mM trabedersen group (95% CI:
9.3–14.8, p ¼ .5153), and 11.0 months (95% CI: 8.7–
13.7, p ¼ .5119) with the standard chemotherapy
group. The OS rate was similar in all 3 groups at 12
months (SupplementaryMaterial,Table S1), butstarting
from 24 months, survival rates were nonsigniﬁcantly
higher in the 10 mM trabedersen group (39%, 95% CI:
24–54) compared with the 80 mM trabedersen group
(29%,95%CI:17–42,p ¼ .2186)andthestandardche-
motherapy group (22%, 95% CI: 12–35, p ¼ .0592).
Case reports of 1 GBM patient and 1 AA patient
treated with 10 mM trabedersen are presented in
Supplementary Material, Figures S1 and S2.
Efﬁcacy in GBM and AA subgroups
As AA and GBM patients differ in their prognoses,
18,19
efﬁcacy analyses were repeated on an exploratory basis
separately for the 2 subpopulations of AA and GBM
patients.
GBM patients—The primary efﬁcacy population
included 95 patients with recurrent/refractory GBM:
28 were treated with 10 mM trabedersen, 34 with
80 mM trabedersen, and 33 with standard chemother-
apy. Baseline characteristics are shown in Table 1, and
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S2.
In GBM patients, the tumor control rates at 6 months
were comparable in all 3 groups (Table 2): 14% (10 mM
trabedersen), 12% (80 mM trabedersen), and 15%
(standard chemotherapy). Tumor control rates sub-
sequently decreased and were 7% (10 mM trabedersen),
3% (80 mM trabedersen), and 9% (standard chemother-
apy) after 14 months.
Median survival was 7.3 months (95% CI: 5.0–12.0)
with 10 mM trabedersen compared with 10.9 months
with 80 mM trabedersen (95% CI: 5.6–13.9,
p ¼ .9370), and 10.0 months (95% CI: 7.0–13.0, p ¼
.7310) with standard chemotherapy. At 24 months, OS
was nonsigniﬁcantly higher with 10 mM trabedersen
(20%, 95% CI: 7–36) compared with 80 mM trabeder-
sen (18%, 95% CI: 7–32, p ¼ .6783) and standard che-
motherapy (15%, 95% CI: 6–29, p ¼ .4861)
(Supplementary Material, Table S1). The median of
the prognostic factor age for GBM patients of the
10 mM trabedersen group was higher than in the other
2 treatment groups (56.5 vs 45.5 and 52.0 years)
(Table 1) as well as the number of patients of age .55
years (54% vs 21% and 36%), which may have biased
the survival results for this group.
Furthermore, as it is well known that high-grade
glioma patients with lower age and higher KPS have a
better prognosis,
18,20 an additional exploratory analysis
Table 1. Patient baseline characteristics (primary efﬁcacy population, n ¼ 134): all patients, GBM patients, and AA patients (primary
efﬁcacy population)
Patient characteristics 10 mM trabedersen 80 mM trabedersen Standard chemotherapy
(TMZ/PCV)
All patients n ¼ 40 n ¼ 49 n ¼ 45
Median age (years) 46.5 44.0 45.0
Patients .55 y (%) 17 (43%) 9 (18%) 13 (29%)
Female (%) 13 (33%) 12 (25%) 22 (49%)
Median duration of disease (months) 7.0 6.0 7.0
Previous radiation therapy (%) 35 (88%) 46 (94%) 41 (91%)
Previous surgery (%) 40 (100%) 49 (100%) 45 (100%)
Previous chemotherapy (%) 22 (55%) 26 (53%) 28 (62%)
Karnofsky performance status
90–100 (%) 30 (75%) 34 (69%) 30 (67%)
70–80 (%) 10 (25%) 15 (31%) 14 (31%)
Median tumor volume (mm
3) 24,159 21,510 15,834
GBM patients n ¼ 28 n ¼ 34 n ¼ 33
Median age (years) 56.5 45.5 52.0
Patients .55 y (%) 15 (54%) 7 (21%) 12 (36%)
Female (%) 7 (25%) 10 (29%) 16 (49%)
Median duration of disease (months) 7.0 6.0 7.0
Previous radiation therapy (%) 23 (82%) 32 (94%) 29 (88%)
Previous surgery (%) 28 (100%) 34 (100%) 33 (100%)
Previous chemotherapy (%) 14 (50%) 21 (62%) 21 (64%)
Karnofsky performance status
90 or 100 (%) 22 (79%) 23 (68%) 20 (61%)
70 or 80 (%) 6 (21%) 11 (32%) 12 (36%)
Median tumor volume (mm
3) 27,072 26,885 17,664
AA patients n ¼ 12 n ¼ 15 n ¼ 12
Median age (years) 39.0 40.0 36.5
Patients .55 y (%) 2 (17%) 2 (13%) 1 (8%)
Female (%) 6 (50%) 2 (13%) 6 (50%)
Median duration of disease (months) 5.5 7.0 8.0
Previous radiation therapy (%) 12 (100%) 14 (93%) 12 (100%)
Previous surgery (%) 12 (100%) 15 (100%) 12 (100%)
Previous chemotherapy (%) 8 (67%) 5 (33%) 7 (58%)
Karnofsky performance status
90–100 (%) 8 (67%) 11 (73%) 10 (83%)
70–80 (%) 4 (33%) 4 (27%) 2 (17%)
Median tumor volume (mm
3) 19,976 14,346 15,701
AA, anaplastic astrocytoma; GBM, glioblastoma multiforme; PCV, procarbazine/CCNU (lomustine)/vincristine; TMZ, temozolomide.
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prognostic factors age ≤55 years and KPS .80%.
This subgroup included 45 patients (primary efﬁcacy
population): 9 were treated with 10 mM trabedersen,
21 with 80 mM trabedersen, and 15 with standard che-
motherapy. Both trabedersen groups showed favorable
survival results, especially the 10 mM trabedersen
group. Median survival for this group was 12.0
months (95% CI: 5.9 to not deﬁned [ND]) compared
with 10.1 months (95% CI: 7.8–13.7, p ¼ .2972) for
standard chemotherapy. At 12 months, OS was 40%
(95% CI: 6–74) with 10 mM trabedersen and 40%
(95% CI: 15–65) with standard chemotherapy. Of
note, at 2 and 3 years, the OS rate was 3-fold higher
for 10 mM trabedersen (40%, 95% CI: 6–74) compared
with standard chemotherapy (13%, 95% CI: 0–31).
AA patients—The primary efﬁcacy population included
39 patients with recurrent AA: 12 were treated with
10 mM trabedersen, 15 with 80 mM trabedersen, and
12 with standard chemotherapy. Baseline characteristics
are shown in Table 1, and safety results are given in
Supplementary Material, Table S2.
In AA patients, the tumor control rate was nonsigni-
ﬁcantly higher with 10 mM trabedersen at 6 months
(75%) compared with 80 mM trabedersen (40%, p ¼
.1302) and standard chemotherapy (58%, p ¼ .6668)
and signiﬁcantly higher vs standard chemotherapy at
14 months (58% vs 20% with 80 mM trabedersen, p
¼ .1534, and 0% with standard chemotherapy, p ¼
.0032) (Fig. 1A, Table 2). The median duration of
response was 29.1 months (95% CI: 4.1–49.8) with
10 mM trabedersen, 24.0 months (95% CI: 2.3–44.9)
with 80 mM trabedersen, and 8.0 months (95% CI:
ND) with standard chemotherapy. The median time to
progression was 22.4 months (95% CI: 1.2–42.0) with
10 mM trabedersen, 3.4 months (95% CI: 1.2–7.8)
with 80 mM trabedersen, and 13.0 months (95% CI:
3.7–14.3) with standard chemotherapy.
Median survival in AA patients was considerably
longer in the trabedersen groups: 39.1 months (95%
CI 31.6 to ND) for 10 mM trabedersen and 35.2
months (95% CI: 13.9–43.1) for 80 mM trabedersen
compared with 21.7 months (95% CI: 10.1–37.4) for
standard chemotherapy (Fig. 1B and C), resulting in a
median survival beneﬁt of 17.4 months for 10 mM trabe-
dersen compared with standard chemotherapy (not sig-
niﬁcant). After 12 months, the 10 mM trabedersen
group had the highest survival rate (92% vs 73% and
67%) (Fig. 1D, Supplementary Material, Table S1).
After 2 years, the 10 mM trabedersen group had a
higher survival rate (83%, 95% CI: 48–96) compared
with the 80 mM trabedersen group (53%, 95% CI:
26–74, p ¼ .2071) and the standard chemotherapy
group (42%, 95% CI: 15–67, p ¼ .1038). At 3 and 4
years, the survival rate remained highest for 10 mM
trabedersen (Fig. 1D, Supplementary Material, Table
S1).
Safety
A total of 98% of patients had at least one AE (Table 3).
AEs of NCI-CTC grade 3 or 4 were reported for 76% of
Table 2. Tumor response: all patients, GBM patients, and AA
patients (primary efﬁcacy population)
Tumor response Number of patients (%)
10 mM
trabedersen
80 mM
trabedersen
Standard
chemotherapy
(TMZ/PCV)
All patients n ¼ 40 n ¼ 49 n ¼ 45
6 months
Tumor control rate
(CR + PR + SD)
13 (33%) 10 (20%) 12 (27%)
Overall response
rate (CR + PR)
2 (5%) 3 (6%) 3 (7%)
Progressive disease 19 (48%) 34 (69%) 23 (51%)
Missing MRI data 8 (20%) 5 (10%) 9 (20%)
14 months
Tumor control rate
(CR + PR + SD)
9 (23%) 4 (8%) 3 (7%)
Overall response
rate (CR + PR)
6 (15%) 3 (6%) 2 (4%)
Progressive disease 22 (55%) 31 (63%) 32 (71%)
Missing MRI data 9 (23%) 14 (29%) 10 (22%)
GBM patients n ¼ 28 n ¼ 34 n ¼ 33
6 months
Tumor control rate
(CR + PR + SD)
4 (14%) 4 (12%) 5 (15%)
Overall response
rate (CR + PR)
0 1 (3%) 0
Progressive disease 16 (57%) 26 (77%) 19 (58%)
Missing MRI data 8 (29%) 4 (12%) 8 (24%)
14 months
Tumor control rate
(CR + PR + SD)
2 (7%) 1 (3%) 3 (9%)
Overall response
rate (CR + PR)
1 (4%) 0 2 (6%)
Progressive disease 20 (71%) 25 (74%) 25 (76%)
Missing MRI data 6 (21%) 8 (24%) 5 (15%)
AA patients n ¼ 12 n ¼ 15 n ¼ 12
6 months
Tumor control rate
(CR + PR + SD)
9 (75%) 6 (40%) 7 (58%)
Overall response
rate (CR + PR)
2 (17%) 2 (13%) 3 (25%)
Progressive disease 3 (25%) 8 (53%) 4 (33%)
Missing MRI data 0 1 (7%) 1 (8%)
14 months
Tumor control rate
(CR + PR + SD)
7 (58%) 3 (20%) 0
Overall response
rate (CR + PR)
5 (42%) 3 (20%) 0
Progressive disease 2 (17%) 6 (40%) 7 (58%)
Missing MRI data 3 (25%) 6 (40%) 5 (42%)
AA, anaplastic astrocytoma; GBM, glioblastoma; PCV,
procarbazine/CCNU (lomustine)/vincristine; TMZ, temozolomide;
CR, complete response; PR, partial response; SD, stable disease.
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standard chemotherapy (Table 4). Most of these events
were nervous system disorders in all 3 groups (66% for
10 mM trabedersen, 59% for 80 mM trabedersen, and
31% for standard chemotherapy), with convulsion,
brain compression, hemiparesis, and brain edema as
the most common. Most AEs were related to the under-
lying disease.
AEs leading to permanent discontinuation of treat-
ment were more common in the trabedersen groups:
46% (10 mM) and 49% (80 mM) compared with
22% for standard chemotherapy (Table 3), but AEs
Fig. 1. Efﬁcacy results in patients with AA (primary efﬁcacy population, n ¼ 39). (A) Tumor control rates (complete response + partial
response + stable disease) at months 6 and 14. *Comparison between 10 mM trabedersen and standard chemotherapy: p ¼ .0032. (B)
Kaplan–Meier plot for patients treated with 10 mM trabedersen (n ¼ 12) vs 80 mM trabedersen (n ¼ 15). (C) Kaplan–Meier plot for
patients treated with 10 mM trabedersen (n ¼ 12) vs standard chemotherapy (n ¼ 12). (D) Overall survival rates.
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with standard chemotherapy: 64% compared with
27% (10 mM trabedersen) and 43% (80 mM trabeder-
sen). These events were most commonly blood and
lymphatic disorders in the standard chemotherapy
group and nervous system disorders as deﬁned above
in the trabedersen groups. Only in 4 patients were
drug-related or possibly drug-related serious adverse
events (SAEs) reported: meningitis, hyponatremia and
brain edema, and thrombocytopenia for 3 patients in
the 80 mM trabedersen group and cerebral disorder
for 1 standard chemotherapy patient. Procedure-
related SAEs were reported in 34% of patients receiv-
ing 10 mM trabedersen and 29% of patients receiving
80 mM trabedersen; for those respective groups,
application site infection occurred in 12% and 10%
of patients and complications associated with catheter
placement occurred in 7% and 2%.
Discussion
This randomized and active-controlled phase IIb study
was designed to be hypothesis generating. It had the
main goals to determine the optimal dose of trabedersen
for use in further clinical development in patients with
high-grade glioma and to compare the efﬁcacy and
safety of trabedersen to standard chemotherapy.
The primary endpoint tumor control rate at 6 months
did not show statistically signiﬁcant differences among
Fig. 1. Continued
Bogdahn et al.: Trabedersen in high-grade glioma
138 NEURO-ONCOLOGY † JANUARY 2011the treatment groups. Endpoints based on tumor assess-
ments early after treatment start are recognized surro-
gate endpoints for OS, the “gold standard” endpoint
for oncology trials.
21,22 However, it has turned out in
recent years that this may not be appropriate for thera-
pies that have a completely different mode of action
from fast-acting cytotoxic or cytoreductive agents.
22,23
This particularly applies to immuno-based therapies,
such as trabedersen, which rely on building an immune
response over time.
23,24 Indeed, the results of this
study show that the clinically relevant beneﬁcial effect
of trabedersen increases over time, which was visible
especially in the 10 mM trabedersen group and was
most evident at 14 months regarding tumor response
(Table 2). An increase in tumor response over time for
trabedersen had already been observed in phase I/II
studies,
12 where 2 patients had long-lasting complete
tumor remissions appearing several months after
initiation of treatment. One patient from these studies
is still alive and in complete remission more than
8 years after start of trabedersen treatment. The other
patient was in complete remission and died of an unre-
lated cause (myocardial infarction) more than 2 years
after start of trabedersen treatment. Taken together,
the full clinically relevant beneﬁcial effects of trabeder-
sen can be accurately assessed only at later time points
(eg, after 14 months for response assessment and after
24 months for survival assessment), and this ﬁnding
will be incorporated into the design of subsequent, con-
ﬁrmatory studies (see also below).
Despitethefactthattheprimaryendpointdidnotreach
statisticalsigniﬁcance,theresultsindicatethattheoptimal
doseis10 mMtrabedersen,asbothefﬁcacy(tumorcontrol
rate, tumor progression rate, and survival rate) and safety
resultstendedtobesuperiorforthe10 mMdosecompared
with the 80 mM dose, despite the inferior prognosis
(higher age and tumor volume) of the 10 mMg r o u pa t
baseline. Although higher efﬁcacy of the lower dose may
seem counterintuitive, in vitro assays in human GBM
cells have shown that 10 mM trabedersen has a stronger
inhibitory effect upon TGF-b2 secretion when compared
with 80 mM (manuscript in preparation), although the
mechanism for this is not fully understood.
There was an advantage in long-term survival for the
10 mM trabedersen group, especially when compared
Table 3. AE overview (safety population, n ¼ 135)
AE Number of patients (%)
10 mM
trabedersen
(n 5 41)
80 mM
trabedersen
(n 5 49)
Standard
chemotherapy
(TMZ/PCV)
(n 5 45)
At least 1 AE 40 (98%) 48 (98%) 44 (98%)
AEs leading to
discontinuation
of study drug
19 (46%) 24 (49%) 10 (22%)
AEs drug related or
possibly drug
related
11 (27%) 21 (43%) 29 (64%)
SAEs 32 (78%) 37 (76%) 18 (40%)
SAEs drug related
or possibly drug
related
0 3 (6%) 1 (2%)
SAEs procedure
related
14 (34%) 14 (29%) n.a.*
SAEs with outcome
death
11 (27%) 17 (35%) 10 (22%)
AE, adverse event; PCV, procarbazine/CCNU (lomustine)/
vincristine; SAE, serious adverse event; TMZ, temozolomide.
*n.a., not applicable, no medical device was used.
Table 4. Patients with NCI-CTC toxicity grade 3/4A Ei n≥10%
of patients in any group (safety population, n ¼ 135)
AEs Number of patients (%)
10 mM
trabedersen
(n 5 41)
80 mM
trabedersen
(n 5 49)
Standard
chemotherapy
(TMZ/PCV)
(n 5 45)
Patients with
NCI-CTC
toxicity grade 3
or 4 AEs
31 (76%) 37 (76%) 27 (60%)
Blood and
lymphatic
system
disorders
2 (5%) 4 (8%) 5 (11%)
General
disorders and
administration
site conditions
10 (24%) 3 (6%) 7 (16%)
Infections and
infestations
brain abscess
3 (7%) 6 (12%) 0
Injury,
poisoning,
and
procedural
complications
7 (17%) 8 (16%) 0
Investigations 6 (15%) 4 (8%) 5 (11%)
Karnofsky
scale
worsened
4 (10%) 4 (8%) 4 (9%)
Nervous system
disorders
27 (66%) 29 (59%) 14 (31%)
Aphasia 6 (15%) 5 (10%) 2 (4%)
Brain
compression
3 (7%) 5 (10%) 2 (4%)
Brain edema 11 (27%) 10 (20%) 2 (4%)
Convulsion 5 (12%) 4 (8%) 3 (7%)
Depressed
level of
consciousness
5 (12%) 2 (4%) 0
Headache 4 (10%) 5 (10%) 3 (7%)
Hemiparesis 11 (27%) 11 (22%) 1 (2%)
Intracranial
pressure
increased
8 (20%) 7 (14%) 2 (4%)
Neurological
symptom
7 (17%) 4 (8%) 2 (4%)
Psychiatric
disorders
5 (12%) 3 (6%) 1 (2%)
AE, adverse event; NCI-CTC, National Cancer Institute–Common
Toxicity Criteria; PCV, procarbazine/CCNU (lomustine)/vincristine;
TMZ, temozolomide.
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lation, the 2-year survival rate for 10 mM trabedersen
was 39% vs 22% for standard chemotherapy. The
beneﬁcial effect of 10 mM trabedersen concerning the
2-year survival rate was even more pronounced in
patients with GBM aged ≤55 years with KPS .80%
(40% vs 13%) and patients with AA (83% vs 42%).
Remarkably, the median survival of patients with AA
treated with 10 mM trabedersen exceeded that of stan-
dard chemotherapy by 17.4 months (39.1 vs 21.7
months). However, it has to be taken into consideration
that the sample sizes of the AA subgroup and the group
with GBM patients aged ≤55 years with KPS .80%
were small and, therefore, restrict generalization of the
results. Despite the clinical relevance of the treatment
effects observed with trabedersen and the consistency
with ﬁndings from previous phase I/II studies,
12 the
hypotheses generated in this phase II study need to be
conﬁrmed in prospective clinical studies. To this end, a
randomized and controlled phase III study in patients
with AA has been initiated (see below).
In this study, the proportion of patients with AEs con-
sidered related or possibly related to the study drug was
highest in the standard chemotherapy group and lowest
in the 10 mM trabedersen group. The patients treated
with trabedersen had a higher rate of NCI-CTC grade
3/4 AEs than patients in the standard chemotherapy
group, mainly regarding neurological events. The exact
reason(s) for this has not been fully clariﬁed to date
and will be closely examined in current and upcoming
studies.
Part of the reason for the higher frequency of AEs in
the trabedersen groups may be that there were more
scheduled study visits for the patients (up to 23 visits)
compared with those with standard chemotherapy (up
to 9 visits), thus allowing more chances for the obser-
vation of AEs. Moreover, all patients of the trabedersen
groups had biopsies taken before start of therapy and 20
patients at 3 months after start of therapy, while no
biopsies were taken from patients of the control group.
Generally, the frequency and nature of the reported
events were typical for patients with primary brain
tumors who usually have a large number of accompany-
ing neurological disorders.
25,26 One reason for more
neurological AEs observed in the trabedersen groups
may be the mode of administration of trabedersen
through CED (ie, the infusion process through an
implanted catheter).
12 Although events related to the
implantation and the procedure of drug administration
cannot be completely avoided, those observed during
this study were manageable, and their incidence can be
furtherreducedbyintensiﬁedtrainingoftheinvestigators.
The ﬁnding that in the 10 mM trabedersen group
more patients were assessed with CR or PR at month
14 than at month 6 (Table 2) supports the hypothesis
from preclinical and phase I/II data that trabedersen
acts mainly by inducing an immune response against
the tumor. This is further supported by the fact that
these responses continue to increase long after discon-
tinuation of trabedersen—for instance, from SD to
partial and even CRs without further antitumor
treatment (see Supplementary Material, Figures S1 and
S2). The suppression of immune reactions is commonly
observed in patients with high-grade glioma.
27 A
major factor contributing to the suppression of the
immune system is TGF-b2, as it has multiple effects on
immunoregulatory functions, including the inhibition
of lymphokine-activated killer cells and T-lymphocyte
development and interleukin-2–dependent growth of T
cells.
5,28–31 Thus, the transient reduction in TGF-b2
levels via the antisense compound trabedersen may
reverse TGF-b2–mediated immunosuppression. This
may lead to the induction of a comprehensive, adaptive
anticancer immune response that eliminates even
residual cancer cells and has the potential to translate
into a beneﬁcial long-term outcome for patients. An
immuno-based anticancer response is also in line with
the observation in a previous phase I/II study where 1
AA patient had several localizations of the tumor in
both brain hemispheres. All these tumor lesions
receded completely after local therapy of only 1 tumor
lesion with trabedersen.
12 This phenomenon was also
observed in patients of this phase IIb study.
Pseudoprogression, a transient initial increase of the
enhancing lesion,
32 was seen in about 10% of
trabedersen-treated patients in this study. In these
patients, pseudoprogression was associated with a favor-
able survival (manuscript in preparation), as has been
reported previously in high-grade glioma patients
treated with radiotherapy and TMZ.
33
In conclusion, 10 mM trabedersen represents
the optimal dose for further clinical development of tra-
bedersen. The 6-month intratumoral CED technique
was found to be safe and well tolerated.
On the basis of the promising results of this study, the
randomized, active-controlled phase III study
SAPPHIRE (Efﬁcacy and Safety of AP 12009 in Adult
Patients with Recurrent or Refractory Anaplastic
Astrocytoma [WHO grade III] as Compared to
Standard Treatment with Temozolomide or BCNU: A
Randomized, Actively Controlled, Open-label Clinical
Phase III Study) in patients with recurrent or refractory
AA has been initiated to compare the 14-month pro-
gression and 24-month survival rates and median OS of
10 mM trabedersen with standard chemotherapy.
Additional survival and tumor response parameters as
well as quality of life and safety will also be assessed in
the study.
Supplementary Material
Supplementary Material is available at Neuro-Oncology
online.
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